mycoreobjectrosdok_disshab_0000002985rosdok_disshab_0000002985rosdokdisshabrosdok_derivate_00002086512023-08-08T10:15:35.565Z2023-07-04T08:48:57.187ZadministratoreditorMSpublished1rosdok_derivate_0000208651truetruederivate_types:fulltextVolltextfulltextwf_edit_epub wf_register_epubstate:publishedstate:publishedveröffentlichtpublishedrosdok/id000043301851554688Oau2023-07-042023-08-05T19:23:04ZrdaConverted from PICA to MODS using Pica2Mods XSLT Transformer 2.7 [SCM: "0c0e7a3c226a4a0cbcbec39b493c3c5257339ab8" "v2.7" "2023-08-04T00:00:00+0200"] with mode 'DEFAULT'.DissertationHochschulschriftCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsKey proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).YixuanMa1991 -VerfasserInaut1294474375ChristianJunghanß1969 -AkademischeR BetreuerIndgs1181185870000-0003-4707-777XUniversitätsmedizin RostockMatthiasSendler1980 -AkademischeR BetreuerIndgs10255669200000-0001-6494-4105Universitätsmedizin GreifswaldRobertJaster1964 -AkademischeR BetreuerIndgs122279085Universitätsmedizin Rostock38329-6Universität Rostock1419 -Grad-verleihende Institutiondgg1029510660Universitätsmedizin RostockGrad-verleihende Institutiondgghttp://purl.uni-rostock.de/rosdok/id00004330urn:nbn:de:gbv:28-rosdok_id00004330-310.18453/rosdok_id00004330610 Medizin, GesundheitUniversitätsmedizinalle Rechte vorbehaltenNutzungsrechte erteiltLizenz Metadaten: CC0frei zugänglich (Open Access)en2022Universität RostockRostockmonographic202320222023Universitätsbibliothek RostockRostock2023Universitätsbibliothek Rostockhttp://purl.uni-rostock.de/rosdok/id00004330Enthält ZeitschriftenartikelThe results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock)[{"name":"Junghanß, Christian","affil":"Universitätsmedizin Rostock"},{"name":"Sendler, Matthias","affil":"Universitätsmedizin Greifswald"},{"name":"Jaster, Robert","affil":"Universitätsmedizin Rostock"}]vorgelegt von Yixuan MaJunghanß, ChristianUniversitätsmedizin RostockSendler, MatthiasUniversitätsmedizin GreifswaldJaster, RobertUniversitätsmedizin Rostockdoctype:epubdoctype:epubDokumenttypDocument typedoctype:epub.dissertationdoctype:epub.dissertationDissertationdoctoral thesisdiniPublType:doctoralThesis diniPublType2022:PhDThesis XMetaDissPlusThesisLevel:thesis.doctoralinfo:eu-repo/semantics/doctoralThesisdocumentnatureOfContent:ppn_105825778natureOfContent:ppn_105825778HochschulschriftdiniPublType2022:DoctoralThesisdiniPublType2022:DoctoralThesisDissertation oder HabilitationDoctoral thesisDRIVERdiniPublType2022:PhDThesisdiniPublType2022:PhDThesisDissertationPhD thesisKDSF (Pu34)XMetaDissPlusThesisLevel:thesis.doctoralXMetaDissPlusThesisLevel:thesis.doctoralDoktorarbeitdoctoral thesisSDNB:610SDNB:610610 Medizin, Gesundheit610 Medical sciences Medicineinstitution:unirostockinstitution:unirostockUniversität RostockUniversity of RostockUniversität RostockUniversität RostockUni.Rostockhttp://d-nb.info/gnd/38329-6institution:unirostock.umrinstitution:unirostock.umrUniversitätsmedizinUniversity MedicineUniversität Rostock. UniversitätsmedizinUniversitätsmedizinUni.Rostock.Fakultaet.MEDhttp://d-nb.info/gnd/1029510660licenseinfo:worklicenseinfo:workWerkworklicenseinfo:work.rightsreservedlicenseinfo:work.rightsreservedalle Rechte vorbehaltenall rights reserved/creativecommons/r/reserved/0.9/88x31.png[DE-28]Urheberrechtsschutz 1.0$gRights Statements$uhttp://rightsstatements.org/vocab/InC/1.0/http://rightsstatements.org/vocab/InC/1.0/http://rightsstatements.org/vocab/InC/1.0/licenseinfo:depositlicenseinfo:depositVeröffentlichungsgenehmigungpermission to storelicenseinfo:deposit.rightsgrantedlicenseinfo:deposit.rightsgrantedNutzungsrechte erteiltrights grantedlicenseinfo:metadatalicenseinfo:metadataLizenzen für Metadatenlicenseinfo:metadata.cc0licenseinfo:metadata.cc0Lizenz Metadaten: CC0license metadata: CC0/creativecommons/p/zero/1.0/88x31.pnghttps://creativecommons.org/publicdomain/zero/1.0/accesscondition:openaccessaccesscondition:openaccessfrei zugänglich (Open Access)open accesshttp://purl.org/coar/access_right/c_abf2OAfreeinfo:eu-repo/semantics/openAccess[DE-28]Open Access$gControlled Vocabulary for Access Rights$uhttp://purl.org/coar/access_right/c_abf2rfc5646:enrfc5646:enEnglischEnglishengengCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsgnd:1294474375gnd:118118587orcid:0000-0003-4707-777Xgnd:1025566920orcid:0000-0001-6494-4105gnd:122279085gnd:38329-6gnd:1029510660gnd:1294474375gnd:118118587orcid:0000-0003-4707-777Xgnd:1025566920orcid:0000-0001-6494-4105gnd:122279085gnd:38329-6gnd:1029510660rosdok_disshab_0000002985-d2198261e52gnd:1294474375Yixuan MaYixuan Marosdok_disshab_0000002985-d2198261e66gnd:118118587orcid:0000-0003-4707-777XChristian JunghanßChristian Junghanßrosdok_disshab_0000002985-d2198261e83gnd:1025566920orcid:0000-0001-6494-4105Matthias SendlerMatthias Sendlerrosdok_disshab_0000002985-d2198261e100gnd:122279085Robert JasterRobert Jasterrosdok_disshab_0000002985-d2198261e116gnd:38329-6Universität RostockUniversität Rostockrosdok_disshab_0000002985-d2198261e127gnd:1029510660Universitätsmedizin RostockUniversitätsmedizin RostockYixuan MaChristian JunghanßMatthias SendlerRobert JasterUniversität RostockUniversitätsmedizin RostockYixuan MaChristian JunghanßMatthias SendlerRobert JasterUniversität RostockUniversitätsmedizin RostockYixuan MaRostockUniversität Rostockepub.dissertationhttp://purl.uni-rostock.de/rosdok/id00004330urn:nbn:de:gbv:28-rosdok_id00004330-310.18453/rosdok_id00004330Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).20222022Enthält ZeitschriftenartikelThe results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock)[{"name":"Junghanß, Christian","affil":"Universitätsmedizin Rostock"},{"name":"Sendler, Matthias","affil":"Universitätsmedizin Greifswald"},{"name":"Jaster, Robert","affil":"Universitätsmedizin Rostock"}]vorgelegt von Yixuan Maepub.dissertation1 Ma_Dissertation_2023.pdf 54272016 2679b71321f86a80d3c69658e3c64237 rosdok/id000043301851554688Oau2023-07-042023-08-05T19:23:04ZrdaConverted from PICA to MODS using Pica2Mods XSLT Transformer 2.7 [SCM: "0c0e7a3c226a4a0cbcbec39b493c3c5257339ab8" "v2.7" "2023-08-04T00:00:00+0200"] with mode 'DEFAULT'.DissertationHochschulschriftCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsKey proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).YixuanMa1991 -VerfasserInaut1294474375ChristianJunghanß1969 -AkademischeR BetreuerIndgs1181185870000-0003-4707-777XUniversitätsmedizin RostockMatthiasSendler1980 -AkademischeR BetreuerIndgs10255669200000-0001-6494-4105Universitätsmedizin GreifswaldRobertJaster1964 -AkademischeR BetreuerIndgs122279085Universitätsmedizin Rostock38329-6Universität Rostock1419 -Grad-verleihende Institutiondgg1029510660Universitätsmedizin RostockGrad-verleihende Institutiondgghttp://purl.uni-rostock.de/rosdok/id00004330urn:nbn:de:gbv:28-rosdok_id00004330-310.18453/rosdok_id00004330610 Medizin, GesundheitUniversitätsmedizinalle Rechte vorbehaltenNutzungsrechte erteiltLizenz Metadaten: CC0frei zugänglich (Open Access)en2022Universität RostockRostockmonographic202320222023Universitätsbibliothek RostockRostock2023Universitätsbibliothek Rostockhttp://purl.uni-rostock.de/rosdok/id00004330Enthält ZeitschriftenartikelThe results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock)[{"name":"Junghanß, Christian","affil":"Universitätsmedizin Rostock"},{"name":"Sendler, Matthias","affil":"Universitätsmedizin Greifswald"},{"name":"Jaster, Robert","affil":"Universitätsmedizin Rostock"}]vorgelegt von Yixuan Ma Junghanß, Christian Universitätsmedizin Rostock Sendler, Matthias Universitätsmedizin Greifswald Jaster, Robert Universitätsmedizin Rostock 2023-07-04T08:48:57.187Z 2023-08-08T10:15:35.565Z 2023-08-18T10:15:35.570Z {"identifier":"rosdok/id00004330","type":"local_id","additional":"","service":"MCRLocalID","created":"2023-07-04T08:48:57.205Z","registered":"2023-07-04T08:48:57.205Z"} editorMS {"identifier":"urn:nbn:de:gbv:28-rosdok_id00004330-3","type":"dnbUrn","additional":"","service":"RosDokURN","created":"2023-07-04T08:48:57.210Z","registered":"2023-07-05T06:45:54.807Z"} administratorfulltextfile/rosdok_disshab_0000002985/rosdok_derivate_0000208651/Ma_Dissertation_2023.pdfCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsgnd:1294474375gnd:118118587orcid:0000-0003-4707-777Xgnd:1025566920orcid:0000-0001-6494-4105gnd:122279085gnd:38329-6gnd:1029510660gnd:1294474375gnd:118118587orcid:0000-0003-4707-777Xgnd:1025566920orcid:0000-0001-6494-4105gnd:122279085gnd:38329-6gnd:1029510660rosdok_disshab_0000002985-d2198261e52gnd:1294474375Yixuan MaYixuan Marosdok_disshab_0000002985-d2198261e66gnd:118118587orcid:0000-0003-4707-777XChristian JunghanßChristian Junghanßrosdok_disshab_0000002985-d2198261e83gnd:1025566920orcid:0000-0001-6494-4105Matthias SendlerMatthias Sendlerrosdok_disshab_0000002985-d2198261e100gnd:122279085Robert JasterRobert Jasterrosdok_disshab_0000002985-d2198261e116gnd:38329-6Universität RostockUniversität Rostockrosdok_disshab_0000002985-d2198261e127gnd:1029510660Universitätsmedizin RostockUniversitätsmedizin RostockYixuan MaChristian JunghanßMatthias SendlerRobert JasterUniversität RostockUniversitätsmedizin RostockYixuan MaChristian JunghanßMatthias SendlerRobert JasterUniversität RostockUniversitätsmedizin RostockYixuan MaRostockUniversität Rostockepub.dissertationhttp://purl.uni-rostock.de/rosdok/id00004330urn:nbn:de:gbv:28-rosdok_id00004330-310.18453/rosdok_id00004330Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).20222022Enthält ZeitschriftenartikelThe results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock)[{"name":"Junghanß, Christian","affil":"Universitätsmedizin Rostock"},{"name":"Sendler, Matthias","affil":"Universitätsmedizin Greifswald"},{"name":"Jaster, Robert","affil":"Universitätsmedizin Rostock"}]vorgelegt von Yixuan Ma[xslt]Saxonrosdok/id00004330https://purl.uni-rostock.de/rosdok/id00004330185155468810.18453/rosdok_id00004330urn:nbn:de:gbv:28-rosdok_id00004330-3Yixuan MaMa YixuanCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsDissertationdoctoral thesisUniversität Rostock, 2022Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the…Yixuan MaCharacterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgroundsUniversitätsbibliothek Rostockhttp://purl.uni-rostock.de/rosdok/id00004330YixuanMa1991 -VerfasserInaut1294474375ChristianJunghanß1969 -AkademischeR BetreuerIndgs1181185870000-0003-4707-777XUniversitätsmedizin RostockMatthiasSendler1980 -AkademischeR BetreuerIndgs10255669200000-0001-6494-4105Universitätsmedizin GreifswaldRobertJaster1964 -AkademischeR BetreuerIndgs122279085Universitätsmedizin Rostock38329-6Universität Rostock1419 -Grad-verleihende Institutiondgg1029510660Universitätsmedizin RostockGrad-verleihende Institutiondgg[purl]http://purl.uni-rostock.de/rosdok/id00004330[urn]urn:nbn:de:gbv:28-rosdok_id00004330-3[doi]10.18453/rosdok_id00004330open_access20222022epoch:21th_centuryrfc5646:endoctype:epub.dissertationaccesscondition:openaccessSDNB:610institution:unirostock.umrstate:published